Rare diseases
Investigational molecules
Locations
Back to Greece6 clinical trials in Peristeri, Greece. Every trial is listed in the EU Clinical Trials Register and updated daily.
Effect of zenagamtide on major adverse cardiovascular events in overweight or obese adults with established atherosclerotic cardiovascular disease
GreeceEfficacy and safety of oral semaglutide for weight loss in adults with overweight or obesity
GreeceStudy comparing two forms of cagrilintide with placebo for weight loss in adults with overweight or obesity
GreeceStudy of Zenagamtide (NNC0487-0111) versus placebo in patients with heart failure with preserved or mildly reduced ejection fraction and obesity
GreeceStudy of zenagamtide versus insulin glargine in adults with type 2 diabetes and high cardiovascular risk uncontrolled on oral medications
GreeceWeight loss in adults with obesity (with or without type 2 diabetes) using cagrilintide and semaglutide: a study of two dose levels versus semaglutide alone
GreeceThe busiest research cities in the country
What the registry says about research in the country
In Peristeri, researchers are evaluating a weekly injectable agent for patients with HFpEF or HFmrEF who also have obesity, aiming to lower the combined risk of cardiovascular death and heart‑failure hospitalisations.
Both studies are actively recruiting, involve 25 investigators, and seek to improve treatment options for a growing heart‑failure population.
Clinical trials in the city are comparing two formulations of injectable cagrilintide and a placebo, as adjuncts to diet and activity counseling, to achieve meaningful weight loss in participants with excess body weight.
The recruiting studies involve a dedicated team of investigators and aim to expand therapeutic options for metabolic health.
Tell us about your condition – we search every trial in Europe and connect you with the right site.
